These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 12121565)

  • 1. Rapid response to infliximab in severe pustular psoriasis, von Zumbusch type.
    Newland MR; Weinstein A; Kerdel F
    Int J Dermatol; 2002 Jul; 41(7):449-52. PubMed ID: 12121565
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of recalcitrant pustular psoriasis with infliximab: effective reduction of chemokine expression.
    Benoit S; Toksoy A; Bröcker EB; Gillitzer R; Goebeler M
    Br J Dermatol; 2004 May; 150(5):1009-12. PubMed ID: 15149518
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Successful treatment of Von Zumbusch pustular psoriasis with infliximab.
    Trent JT; Kerdel FA
    J Cutan Med Surg; 2004; 8(4):224-8. PubMed ID: 16091999
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A dramatic response to a single dose of infliximab as rescue therapy in acute generalized pustular psoriasis of von Zumbusch associated with a neutrophilic cholangitis.
    Chandran NS; Chong WS
    Australas J Dermatol; 2010 Feb; 51(1):29-31. PubMed ID: 20148838
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Response of severe psoriasis to infliximab.
    Mang R; Stege H; Ruzicka T; Krutmann J
    Dermatology; 2002; 204(2):156-7. PubMed ID: 11937748
    [No Abstract]   [Full Text] [Related]  

  • 6. Effect of infliximab on health-related quality of life and disease activity by body region in patients with moderate-to-severe psoriasis and inadequate response to etanercept: results from the PSUNRISE trial.
    Kalb RE; Blauvelt A; Sofen HL; Chevrier M; Amato D; Calabro S; Wang J; Schenkel B; Gottlieb AB
    J Drugs Dermatol; 2013 Aug; 12(8):874-80. PubMed ID: 23986160
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Treatment of severe refractory psoriasis with infliximab].
    Mahiques Santos L; Martínez-Menchón T; Sánchez Carazo JL; Oliver Martínez V; Soriano Navarro CJ; Fortea Baixauli JM
    Med Clin (Barc); 2004 Nov; 123(17):657-8. PubMed ID: 15563800
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Palmoplantar pustular psoriasis: successful therapy with efalizumab after non-response to infliximab.
    Wozel G; Vitez L
    Acta Derm Venereol; 2008; 88(2):169-70. PubMed ID: 18311451
    [No Abstract]   [Full Text] [Related]  

  • 9. Pharmacodynamic and pharmacokinetic response to anti-tumor necrosis factor-alpha monoclonal antibody (infliximab) treatment of moderate to severe psoriasis vulgaris.
    Gottlieb AB; Masud S; Ramamurthi R; Abdulghani A; Romano P; Chaudhari U; Dooley LT; Fasanmade AA; Wagner CL
    J Am Acad Dermatol; 2003 Jan; 48(1):68-75. PubMed ID: 12522373
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recalcitrant, generalized pustular psoriasis: rapid and lasting therapeutic response to antitumour necrosis factor-alpha antibody (infliximab).
    Schmick K; Grabbe J
    Br J Dermatol; 2004 Feb; 150(2):367. PubMed ID: 14996114
    [No Abstract]   [Full Text] [Related]  

  • 11. [Treatment of severe refractory psoriasis with infliximab. Clinical outcomes after one year of therapy].
    Mahiques Santos L; Martínez Menchón T; Sánchez Carazo JL; Fortea Baixauli JM
    Med Clin (Barc); 2005 Jun; 125(4):159. PubMed ID: 15989862
    [No Abstract]   [Full Text] [Related]  

  • 12. A review of the treatment of psoriasis with infliximab.
    Vamvouris T; Hadi S
    Rev Recent Clin Trials; 2006 Sep; 1(3):201-5. PubMed ID: 18473973
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Programmed cell death of keratinocytes in infliximab-treated plaque-type psoriasis.
    Krüger-Krasagakis S; Galanopoulos VK; Giannikaki L; Stefanidou M; Tosca AD
    Br J Dermatol; 2006 Mar; 154(3):460-6. PubMed ID: 16445776
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A follow-up study in 28 patients treated with infliximab for severe recalcitrant psoriasis: evidence for efficacy and high incidence of biological autoimmunity.
    Poulalhon N; Begon E; Lebbé C; Lioté F; Lahfa M; Bengoufa D; Morel P; Dubertret L; Bachelez H
    Br J Dermatol; 2007 Feb; 156(2):329-36. PubMed ID: 17223874
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acute treatment of generalized pustular psoriasis of von Zumbusch with single-dose infliximab.
    Smith N; Harms KL; Hines AC; Harms PW; Gudjonsson JE; Hristov AC; Wang F
    J Am Acad Dermatol; 2013 Jun; 68(6):e187-9. PubMed ID: 23680215
    [No Abstract]   [Full Text] [Related]  

  • 16. Life-threatening pustular and erythrodermic psoriasis responding to infliximab.
    Lewis TG; Tuchinda C; Lim HW; Wong HK
    J Drugs Dermatol; 2006 Jun; 5(6):546-8. PubMed ID: 16774108
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Efficacy of infliximab in patients with moderate and severe psoriasis treated with infliximab (Remicade)].
    Valdés A Mdel P; Schroeder H F; Roizen G V; Honeyman M J; Sánchez M L
    Rev Med Chil; 2006 Mar; 134(3):326-31. PubMed ID: 16676105
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Infliximab: efficacy in psoriasis.
    Arsiwala S
    Indian J Dermatol Venereol Leprol; 2013 Jul; 79 Suppl 7():S25-34. PubMed ID: 23974692
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Infliximab monotherapy in psoriasis: a case of rapid clinical and histological response.
    Vincek V; Jacob SE; Nassiri M; Herbert LM; Nadji M; Kerdel FA
    Int J Dermatol; 2004 Apr; 43(4):303-8. PubMed ID: 15090021
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Infliximab for the treatment of psoriasis in Greece: 4 years of clinical experience at a single centre.
    Antoniou C; Stefanaki I; Stratigos A; Moustou E; Vergou T; Stavropoulos P; Avgerinou G; Rigopoulos D; Katsambas AD
    Br J Dermatol; 2010 May; 162(5):1117-23. PubMed ID: 19906069
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.